Introduction:
Low-grade gliomas can appear in any region of the neuroaxis. When located in particular areas of the brain, seizures can be a common manifestation at diagnosis. Characteristically, temporal-mesial and insular lobe areas tend to harbor such lesions (1). Not infrequently, tumor-associated epilepsy may be hard to control and even refractory to multiple antiepileptic drugs (AED). In the context of long-term epilepsy associated tumors (LEATS), extensive neurosurgical interventions are usually necessary to improve seizures control (2). Quality of life of children and adolescents under multiple AED and/or with post-surgical neurologic sequelae must be taken into consideration when proposing a treatment plan for these challenging patients. Frequently, these tumors tend to present an aberrant activation of MAPK signaling either through a BRAF tandem duplication or V600E mutation. The development and introduction of oral targeted therapies includingBRAF inhibitors are changing the treatment paradigm for these patients. However, its clinical efficacy in tumor-associated epilepsy has not been reported.